These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 30772960

  • 61. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.
    Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [Abstract] [Full Text] [Related]

  • 62. [68Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
    Mainta IC, Neroladaki A, Wolf NB, Benamran D, Boudabbous S, Zilli T, Garibotto V.
    J Nucl Med; 2024 Sep 03; 65(9):1376-1382. PubMed ID: 39117453
    [Abstract] [Full Text] [Related]

  • 63. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer.
    Xue AL, Kalapara AA, Ballok ZE, Levy SM, Sivaratnam D, Ryan A, Ramdave S, O'Sullivan R, Moon D, Grummet JP, Frydenberg M.
    J Urol; 2022 Feb 03; 207(2):341-349. PubMed ID: 34546815
    [Abstract] [Full Text] [Related]

  • 64. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
    Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L.
    Nucl Med Commun; 2016 Nov 03; 37(11):1169-79. PubMed ID: 27333090
    [Abstract] [Full Text] [Related]

  • 65. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.
    Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.
    BJU Int; 2020 Jul 03; 126(1):83-90. PubMed ID: 31260602
    [Abstract] [Full Text] [Related]

  • 66. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM.
    BMC Cancer; 2020 Aug 05; 20(1):723. PubMed ID: 32758168
    [Abstract] [Full Text] [Related]

  • 67. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K.
    Eur Urol; 2023 Jul 05; 84(1):36-48. PubMed ID: 37032189
    [Abstract] [Full Text] [Related]

  • 68. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
    Onal C, Torun N, Oymak E, Guler OC, Reyhan M, Yapar AF.
    Ann Nucl Med; 2020 Jun 05; 34(6):388-396. PubMed ID: 32221791
    [Abstract] [Full Text] [Related]

  • 69. 68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment.
    Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, Loening AM, Ghanouni P, Sonn G, Iagaru A.
    J Nucl Med; 2022 Dec 05; 63(12):1822-1828. PubMed ID: 35512996
    [Abstract] [Full Text] [Related]

  • 70. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L, McBean R, Yaxley J, Wong D.
    J Med Imaging Radiat Oncol; 2019 Jun 05; 63(3):318-323. PubMed ID: 30840361
    [Abstract] [Full Text] [Related]

  • 71. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
    Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Casale P, Pietro D, Bevilacqua G, Balzarini L, Buffi NM, Guazzoni G, Lazzeri M.
    Eur Urol Focus; 2021 Jul 05; 7(4):764-771. PubMed ID: 32312701
    [Abstract] [Full Text] [Related]

  • 72. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive].
    Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN.
    Prog Urol; 2017 Jul 05; 27(8-9):474-481. PubMed ID: 28576423
    [Abstract] [Full Text] [Related]

  • 73. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer.
    Kubilay E, Akpinar Ç, Oǧuz ES, Araz MS, Soydal Ç, Baltacı S, Ürün Y, Süer E.
    Urol Oncol; 2022 Sep 05; 40(9):408.e19-408.e25. PubMed ID: 35902300
    [Abstract] [Full Text] [Related]

  • 74. The clinical consequences of routine 68Ga-PSMA-11 PET/CT in patients with newly diagnosed prostate cancer, ISUP grade 5 and no metastases based on standard imaging - preliminary results.
    Zacho HD, Nalliah S, Petersen A, Petersen LJ.
    Scand J Urol; 2022 Sep 05; 56(5-6):353-358. PubMed ID: 36073096
    [Abstract] [Full Text] [Related]

  • 75. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
    Alvim R, Nagar K, Das S, Lebdai S, Wong N, Somma A, Hughes C, Thomas J, Monette S, Scherz A, Kim K, Grimm J, Coleman JA.
    Eur Urol Focus; 2021 Mar 05; 7(2):472-478. PubMed ID: 31227464
    [Abstract] [Full Text] [Related]

  • 76. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.
    Nucl Med Commun; 2017 Nov 05; 38(11):956-963. PubMed ID: 28922335
    [Abstract] [Full Text] [Related]

  • 77. Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients.
    Özülker F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Nov 05; 38(2):100-105. PubMed ID: 30514659
    [Abstract] [Full Text] [Related]

  • 78. Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer.
    El Hajj A, Yacoub B, Mansour M, Khauli R, Bulbul M, Nassif S, Haidar MB.
    Medicine (Baltimore); 2019 Nov 05; 98(44):e17491. PubMed ID: 31689752
    [Abstract] [Full Text] [Related]

  • 79. The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
    Kulkarni M, Hughes S, Mallia A, Gibson V, Young J, Aggarwal A, Morris S, Challacombe B, Popert R, Brown C, Cathcart P, Dasgupta P, Warbey VS, Cook GJR.
    Eur J Nucl Med Mol Imaging; 2020 Mar 05; 47(3):674-686. PubMed ID: 31872280
    [Abstract] [Full Text] [Related]

  • 80. 68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
    Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.
    Asia Pac J Clin Oncol; 2018 Aug 05; 14(4):343-346. PubMed ID: 29663686
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.